Remoxipride

Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).^[2] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.^[2] Remoxipride acts as a selective D₂ and D₃ receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.^[3]

Trade namesRoxiam

Routes of
administrationOral

ATC code

• N05AL04 (WHO)

Legal status

• Withdrawn

Quick facts Clinical data, Trade names ...

Remoxipride

Clinical data
Trade names	Roxiam
Routes of administration	Oral
ATC code	N05AL04 (WHO)
Legal status
Legal status	Withdrawn
Pharmacokinetic data
Bioavailability	96%[1]
Protein binding	89-98%
Metabolism	Hepatic[1]
Elimination half-life	4-7 hours[1]
Excretion	Renal[1]
Identifiers
IUPAC name 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
CAS Number	80125-14-0 N
PubChem CID	54477
DrugBank	DB00409 Y
ChemSpider	49195 Y
UNII	0223RD59PE
KEGG	D02683 Y
ChEMBL	ChEMBL22242 Y
CompTox Dashboard (EPA)	DTXSID6045668
Chemical and physical data
Formula	C16H23BrN2O3
Molar mass	371.275 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN2CCC[C@H]2CNC(=O)c1c(OC)ccc(Br)c1OC
InChI InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1 Y Key:GUJRSXAPGDDABA-NSHDSACASA-N Y
NY (what is this?)  (verify)

Close

Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.^[4] There was some interest in its use in the treatment of treatment-resistant schizophrenia.^[5][6]